Industry & Company News

Facet Life Sciences contributed to and proudly supports the 2025 Mars Shot program, a Society of Nuclear Medicine and Molecular Imaging (SNMMI) initiative that provides funding to developers using nuclear medicine to find novel...

Facet Life Sciences specializes in guiding life science companies through the complex journey of drug, biologic, and medical device development and registration with the US FDA. Facet is pleased to announce the company’s role a...

From The Corner Office Q2 2024Ken VanLuvanee, President & CEO Apologies for the delay—this past quarter, we’ve championed a large number of Sponsor-FDA meetings and have had even more informal interactions in our quest to ...

FACET BY THE NUMBERS Total ESG submissions to FDA Apr – June 2024:  Over 30! Early-Stage Development Highlights 6 formal FDA meetings, 1 investigator-initiated IND, over 25 IND amendments (e.g., new protocols/amendments, CMC up...

Team Focus – New Facet Team Members We are excited to announce the addition of 3 new team members. Eva Raspor, Strategic Regulatory Writer Facet welcomes Eva Raspor to our team as a Strategic Regulatory Writer.  Eva has a...

Facet Donates to SNMMI’s Mars Shot Facet is proud to be a SNMMI Mars Shot Research Fund donor in 2024.  The goal of this fund is to improve and extend the lives of patients with cancer through innovation with radiopharmaceutica...

Facet Attends SNMMI In June, Dr. Lisa Jenkins VanLuvanee attended the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting.  SNMMI is an educational, scientific, research, and networking organization focus...

Facet Attends Psychedelic Therapeutics & Drug Development Conference In May, Dr. Jason Mercer attended the Psychedelic Therapeutics & Drug Development Conference.  This conference brought together academic and industry ...